Literature DB >> 9369398

Laryngofissure and cordectomy for glottic carcinoma limited to the mid third of the mobile true vocal cord.

L Muscatello1, O Laccourreye, B Biacabe, S Hans, M Ménard, D Brasnu.   

Abstract

The objective of this study was to analyze the long-term results of laryngofissure with cordectomy for invasive glottic squamous cell carcinoma limited to the mid third of the mobile true vocal cord. The authors conducted a retrospective review of the medical charts and operative files of 33 patients with invasive glottic carcinoma limited to the mid third of the mobile true vocal cord managed with laryngofissure and cordectomy. A 10-year follow-up was achieved in 30 patients (90.9%). Kaplan-Meier actuarial analysis of survival, local control, nodal recurrence, distant metastasis, and second primary metachronous tumor was performed. The 5-year actuarial survival, local control, nodal recurrence, and distant metastasis estimates were 97%, 100%, 0%, and 0%, respectively. Tracheotomy was never performed. The overall laryngeal preservation rate was 100%. The 5- and 10-year actuarial metachronous second primary tumor estimates were 3% and 11.5%, respectively. The authors' experience suggested that laryngofissure and cordectomy should still be considered a valuable oncologic option for the management of invasive glottic carcinoma limited to the mid third of the mobile true vocal cord.

Entities:  

Mesh:

Year:  1997        PMID: 9369398     DOI: 10.1097/00005537-199711000-00015

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  [Glottic laryngeal carcinoma. Tis, T1 and T2--long term results after laser resection].

Authors:  O König; U Bockmühl; K Haake
Journal:  HNO       Date:  2006-02       Impact factor: 1.284

2.  An empirical study of modified frontolateral partial laryngectomy without tracheotomy.

Authors:  Hongming Xu; Pin Dong; Zhenfeng Sun; Jin Xie
Journal:  Exp Ther Med       Date:  2012-11-28       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.